SecurityGSK / GlaxoSmithKline plc
InstitutionJarislowsky, Fraser Ltd
Shares278,443
Value $ 11,224,000
Related 377372AG2 / Glaxosmithkline Cap Inc. 0.70% 03/18/16
377372AH0 / Glaxosmithkline Cap Inc. 2.80% 03/18/23
377372AJ6 / Glaxosmithkline Cap Inc. 4.20% 03/18/43
377372AA5 / Glaxosmithkline Cap Inc Guaranteed Notes 4.375% 04/15/14
377372AB3 / Glaxosmithkline Cap Inc Guaranteed Notes 5.375% 04/15/34
377373AC9 / Glaxosmithkline Capital 1.50% 05/08/17
377373AD7 / Glaxosmithkline Capital 2.85% 05/08/22
377372AC1 / Glaxosmithkline Capital 4.85% Guaranteed Notes 5/15/13
377372AD9 / Glaxosmithkline Capital 5.65% Guaranteed Notes 5/15/18
377372AE7 / Glaxosmithkline Capital 6.375% Guaranteed Notes 5/15/38
377373AB1 / Glaxosmithkline Capital .75% 05/08/15

Jarislowsky, Fraser Ltd reports 8.30% decrease in ownership of GSK / GlaxoSmithKline plc

August 10, 2018 - Jarislowsky, Fraser Ltd has filed a 13F-HR form disclosing ownership of 278,443 shares of GlaxoSmithKline plc (NYSE:GSK) with total holdings valued at $11,224,000 USD as of June 30, 2018. Jarislowsky, Fraser Ltd had filed a previous 13F-HR on May 14, 2018 disclosing 303,633 shares of GlaxoSmithKline plc at a value of $11,862,000 USD. This represents a change in shares of -8.30 percent and a change in value of -5.38 percent during the quarter.

Other investors with positions similar to Jarislowsky, Fraser Ltd include JP Morgan Chase & Co, United Capital Financial Advisers, Llc, Lincluden Management Ltd, Raymond James Financial Services Advisors, Inc., Freestone Capital Holdings, LLC, and Eversept Partners, Llc.

13F Filings

The Security, Class, and CUSIP columns in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names and cusips.

In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Effective
Date
Form Security Class CUSIP Share
Price
Shares Change
(%)
Value
(x1000)
Change
(%)
Cost
(x1000)
Profit
(x1000)
Return
(%)
2018-06-30 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 39.69 278,443 -8.30 11,224 -5.38 -1,000 362 3.05
2018-03-31 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 37.27 303,633 -20.73 11,862 -12.69 -2,959 1,235 9.09
2017-12-31 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 38.03 383,030 -53.53 13,586 -59.40 -16,780 -3,096 -9.25
2017-09-30 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 41.86 824,206 -2.30 33,462 -8.01 -811 -2,102 -5.78
2017-06-30 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 42.64 843,578 -3.71 36,375 -1.52 -1,387 825 2.23
2017-03-31 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 40.34 876,115 -5.14 36,937 3.85 -1,917 3,285 9.23
2016-12-31 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 40.82 923,631 10.79 35,569 -1.08 3,671 -4,059 -11.29
2016-09-30 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 43.23 833,699 2.83 35,957 2.33 993 -173 -0.49
2016-06-30 13F-HR GlaxoSmithKline plc ADR ADR 37733W105 41.94 810,733 4.88 35,137 12.09 1,582 2,209 7.05
2016-03-31 13F-HR GLAXOSMITHKLINE PLC-SPON ADR ADR 37733W105 40.45 773,021 4.92 31,346 5.45 1,467 152 0.51
2015-12-31 13F-HR GLAXOSMITHKL-ADR ADR 37733W105 39.40 736,748 0.47 29,727 5.44 137 1,396 4.95
2015-09-30 13F-HR GLAXOSMITHKL-ADR ADR 37733W105 40.05 733,283 13.36 28,194 4.65 3,461 -2,208 -8.20
2015-06-30 13F-HR/A-1 GLAXOSMITHKL-ADR ADR 37733W105 43.90 646,864 42.57 26,941 28.66 8,479 -2,477 -11.83
2015-06-30 13F-HR GLAXOSMITHKL-ADR ADR 37733W105 646,864 26,941
2015-03-31 13F-HR GLAXOSMITHKLINE PLC ADR ADR 37733W105 44.44 453,719 17.58 20,939 26.96 3,015 1,432 8.68
2014-12-31 13F-HR GLAXOSMITHKL-ADR ADR 37733W105 44.35 385,873 7.78 16,492 0.21 1,236 -1,201 -7.30
2014-09-30 13F-HR GLAXOSMITHKL-ADR ADR 37733W105 49.72 358,009 -5.05 16,457 -18.39 -947 -2,761 -13.69
2014-06-30 13F-HR GLAXOSMITHKL-ADR SPONSORED ADR 37733W105 377,053 20,165

Related SEC Filings

GSK / GlaxoSmithKline plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009252882_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) GLAXOSMITHKLINE PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DHS4 -------------------------------------------------------- (SEDOL Number) December 31, 2017 ----------------------------------------------------

GSK / GlaxoSmithKline plc / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-30 sec.gov
gb0009252882_012918.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) GLAXOSMITHKLINE PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) B01DHS4 -------------------------------------------------------- (SEDOL Number) December 31, 2017 ----------------------------------------------------

GlaxoSmithKline 3G/A (Passive Acquisition of More Than 5% of Shares)

2017-01-24 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) GLAXOSMITHKLINE PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 0925288 -------------------------------------------------------- (SEDOL Number) December 31, 2016 -------------------------------------------------------- (Date of Event Whic

GlaxoSmithKline 3G/A (Passive Acquisition of More Than 5% of Shares)

2017-01-24 sec.gov
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) GLAXOSMITHKLINE PLC -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 0925288 -------------------------------------------------------- (SEDOL Number) December 31, 2016 -------------------------------------------------------- (Date of Event Whic

GLAXOSMITHKLINE Form SC 13G/A (Acquisition of More Than 5% of Shares)

2016-02-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   SCHEDULE 13G   Under the Securities Exchange Act of 1934 (Amendment No. 1)*     THERAVANCE BIOPHARMA, INC.  (Name of Issuer)     Ordinary Shares (Title of Class of Securities)     G8807B106 (CUSIP Number)     December 31, 2015 (Date of Event Which Requires Filing of this Statement)     Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) x Rule 13d-1(d)  

Related News Stories

Emergent Completes Acquisition of Narcan Maker Adapt Pharma

2018-10-16 zacks
Emergent BioSolutions Inc. (EBS - Free Report) announced that it has closed the acquisition of privately held Adapt Pharma, which will add the latter’s Narcan (naloxone hydrochloride) nasal spray to its portfolio, thereby expanding the company’s presence in the public health threats market. (6-0)

Healthcare 16-24% Target Net Gains Pace WallStars For October

2018-10-15 seekingalpha
Big pharma drug makers and biotech continued to top the healthcare sector by broker targets. WallStars are distinguished by positive broker target price upsides. (34-0)

Stocks To Watch: Was That A Speed Bump?

2018-10-13 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (254-5)

Novartis Presents Positive Data on Sickle Cell Disease Drug

2018-10-10 zacks
Novartis AG (NVS - Free Report) announced positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab. (5-1)

Merck Reports Positive Efficacy Data from Phase III HIV Study

2018-10-05 zacks
Merck and Co. (MRK - Free Report) announced positive efficacy results from the phase III DRIVE-AHEAD study, evaluating the efficacy and safety of Delstrigo in treatment-naïve adults with HIV-1 infection. (4-0)



CUSIP: 37733W105